Disclosure Dr. Andersén reports funding by the state subsidy of Turku University Hospital, travel costs by Cancer Society of Finland and Pfizer, and steering committee membership for Nordic Thoracic Oncology Group. Dr. Aro reports support attending meeting for AstraZeneca and Orion, and eLive Ecosystems stock ownership. Dr. Kaarteenaho reports grants by the Tampere Tuberculosis Foundation, the state subsidy of Oulu University Hospital, consulting fees by Boehringer-Ingelheim, Merck Sharp & Dohme and payment for lecture by Boehringer-Ingelheim, virtual meeting support by Novartis, membership of the board of the Finnish Medical Foundation from January 2020 to December 2022, membership of the Finnish Lung Health Association from January 2021 onward, and randomized controlled trial studies, Boehringer-Ingelheim. Dr. Koivunen reports funding from AstraZeneca, Roche, Cancer Foundation Finland, consulting fees from Roche, AstraZeneca, Janssen, Bristol-Myers Squibb, Merck, Amgen, Novartis, Merck KgA, Sanofi, and Pfizer, payment honoraria by Siemens Healthineers, and part-time employment at Faron Pharmaceuticals. Dr. Mäyränpää reports payments or honoraria from Amgen, AstraZeneca, and Bristol-Myers Squibb, payment for expert testimony for Amgen, and participation on an advisory board for Bristol-Myers Squibb. Dr. Sihvo reports consultation fee from Merck Sharp & Dohme, payment or honoraria from AstraZeneca, Merck Sharp & Dohme, and support for travel from Merck Sharp & Dohme. Dr. Vasankari reports consultation fee from Merck Sharp & Dohme and support for attending meetings from Cancer Society Finland.